Држава: Канада
Језик: Енглески
Извор: Health Canada
ATORVASTATIN (ATORVASTATIN CALCIUM)
Q-GEN PHARMACEUTICALS INC
C10AA05
ATORVASTATIN
10MG
TABLET
ATORVASTATIN (ATORVASTATIN CALCIUM) 10MG
ORAL
90
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0133055001; AHFS:
CANCELLED (UNRETURNED ANNUAL)
2017-09-05
PRODUCT MONOGRAPH Q-GEN ATORVASTATIN® (ATORVASTATIN CALCIUM TABLETS) 10 MG, 20 MG, 40 MG AND 80 MG ATORVASTATIN LIPID METABOLISM REGULATOR Q-Gen Pharmaceuticals Inc. DATE OF PREPARATION: 1100 Central Park West November 30, 2011 Mississauga, ON, L5C 4E5 CONTROL # 150711 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION..............................................................................20 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY..........................................................................................24 SPECIAL HANDLING INSTRUCTIONS .......................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25 PART II: SCIENTIFIC INFORMATION ...............................................................................27 PHARMACEUTICAL INFORMATION..........................................................................27 CLINICAL TRIALS..........................................................................................................28 DETAILED PHA Прочитајте комплетан документ